Enrich KG with 21,086 pathway relations (WikiPathways/GO), 8 skin cell lineages, and ChEMBL/DrugCentral human bioactivities (92,359 total relations, 213,626 evidence rows)
Browse files- README.md +17 -14
- entities.jsonl +0 -0
- evidence.jsonl +2 -2
- ictrp/entities.jsonl +2 -2
- relations.jsonl +2 -2
README.md
CHANGED
|
@@ -38,15 +38,15 @@ database entry, and where licensing allows, the sentence itself.
|
|
| 38 |
|
| 39 |
| | Count |
|
| 40 |
|---|---|
|
| 41 |
-
| Entities | 16,
|
| 42 |
-
| Relations |
|
| 43 |
-
| Measured relations |
|
| 44 |
-
| Evidence rows |
|
| 45 |
-
| Quoted sentences |
|
| 46 |
|
| 47 |
A further 2,464 relations resting only on WHO ICTRP records are published
|
| 48 |
separately under WHO's terms (see [Licensing](#licensing)), bringing the total
|
| 49 |
-
to
|
| 50 |
|
| 51 |
Snapshot of 8 November 2026. Research data, not medical advice.
|
| 52 |
|
|
@@ -56,17 +56,20 @@ Snapshot of 8 November 2026. Research data, not medical advice.
|
|
| 56 |
event is the node of the disease or finding it names, so "herpes zoster" in
|
| 57 |
a trial's safety table and in a paper is one node), 4,223 targets (genes and
|
| 58 |
proteins), 1,577 trials, 1,355 drugs, 1,201 interventions (procedures,
|
| 59 |
-
phototherapy and combination regimens), 873 biomarkers,
|
| 60 |
-
|
|
|
|
| 61 |
|
| 62 |
-
**Relations** (`relations`): changes 28,592 ·
|
| 63 |
-
co_expressed_with 8,367 · treats 3,587 · tested_in 2,735 ·
|
| 64 |
-
|
| 65 |
-
expressed_in
|
| 66 |
|
| 67 |
**Evidence** (`evidence`): one row per source of a relation. Incorporates
|
| 68 |
-
full-text extraction across 2,712 PMC papers with BioRED BiomedBERT
|
| 69 |
-
direct human vitiligo skin punch biopsy co-expression measurements (GSE311770, N=105)
|
|
|
|
|
|
|
| 70 |
A relation stated by several papers or measurements has several rows.
|
| 71 |
|
| 72 |
## Schema
|
|
|
|
| 38 |
|
| 39 |
| | Count |
|
| 40 |
|---|---|
|
| 41 |
+
| Entities | 16,931 |
|
| 42 |
+
| Relations | 89,895 |
|
| 43 |
+
| Measured relations | 60,529 |
|
| 44 |
+
| Evidence rows | 213,626 |
|
| 45 |
+
| Quoted sentences | 77,964 |
|
| 46 |
|
| 47 |
A further 2,464 relations resting only on WHO ICTRP records are published
|
| 48 |
separately under WHO's terms (see [Licensing](#licensing)), bringing the total
|
| 49 |
+
to 92,359 relations.
|
| 50 |
|
| 51 |
Snapshot of 8 November 2026. Research data, not medical advice.
|
| 52 |
|
|
|
|
| 56 |
event is the node of the disease or finding it names, so "herpes zoster" in
|
| 57 |
a trial's safety table and in a paper is one node), 4,223 targets (genes and
|
| 58 |
proteins), 1,577 trials, 1,355 drugs, 1,201 interventions (procedures,
|
| 59 |
+
phototherapy and combination regimens), 873 biomarkers, 807 biological pathways
|
| 60 |
+
(WikiPathways CC0, Gene Ontology CC-BY-4.0, and Reactome), 23 outcomes, 10
|
| 61 |
+
cutaneous cell types, and related mechanisms and phenotypes.
|
| 62 |
|
| 63 |
+
**Relations** (`relations`): changes 28,592 · participates_in 21,086 ·
|
| 64 |
+
associated_with 19,394 · co_expressed_with 8,367 · treats 3,587 · tested_in 2,735 ·
|
| 65 |
+
inhibits 2,385 · causes 1,742 · investigates 1,577 · activates 996 ·
|
| 66 |
+
expressed_in 137 · combined_with 61 · targets 29 · occurs_in 4.
|
| 67 |
|
| 68 |
**Evidence** (`evidence`): one row per source of a relation. Incorporates
|
| 69 |
+
full-text extraction across 2,712 PMC papers with BioRED BiomedBERT,
|
| 70 |
+
direct human vitiligo skin punch biopsy co-expression measurements (GSE311770, N=105),
|
| 71 |
+
WikiPathways (CC0) and experimental Gene Ontology Biological Process (CC-BY-4.0) pathway hierarchies,
|
| 72 |
+
and ChEMBL / DrugCentral human drug-target bioactivities ($p\text{Act} \ge 6.5$).
|
| 73 |
A relation stated by several papers or measurements has several rows.
|
| 74 |
|
| 75 |
## Schema
|
entities.jsonl
CHANGED
|
The diff for this file is too large to render.
See raw diff
|
|
|
evidence.jsonl
CHANGED
|
@@ -1,3 +1,3 @@
|
|
| 1 |
version https://git-lfs.github.com/spec/v1
|
| 2 |
-
oid sha256:
|
| 3 |
-
size
|
|
|
|
| 1 |
version https://git-lfs.github.com/spec/v1
|
| 2 |
+
oid sha256:828ecf70089296521a0230b62b68f765b1588389650f6daa820703ddde41e8b0
|
| 3 |
+
size 99549287
|
ictrp/entities.jsonl
CHANGED
|
@@ -449,7 +449,7 @@
|
|
| 449 |
{"id": 1712, "kind": "trial", "key": "chictr2500099959", "name": "ChiCTR2500099959", "aliases": ["ChiCTR2500099959", "Clinical study of hair follicle organoids for the treatment of vitiligo"], "external_ids": {"ictrp": "ChiCTR2500099959"}}
|
| 450 |
{"id": 1713, "kind": "drug", "key": "dose_escalation_group_it_adopts_a_3_3_dose_escalation_design_subjects_were_sequentially_assigned_to_one_of_three_dose_gr", "name": "Dose escalation group:It adopts a \"\"3+3\"\" dose escalation design. Subjects were sequentially assigned to one of three dose groups, with a concentration of 2×105/mL in the low-dose group, 2×106/mL in the middle-dose group, and 2×107/mLparticles/mL in the high-dose group. The principle of dose escalation was strictly followed, starting with the low dose and increasing sequentially, and 3 subjects were included in each group.\n7 days after the first patient in each dose group was dosed, the 2nd to 3rd patients could be dosed; A seven-day safety assessment for all participants in the previous dose group was completed before the next dose group could be conducted. If the criteria for terminating the trial are met during the dose escalation process, the investigator will discuss and decide to terminate the trial or return to the previous dose group to continue the trial.;Case expansion group (control group):Tacrolimus in combination with 308 phototherapy;Case Expansion Group (Experimental Group):Hair follicle organoid therapy;", "aliases": ["Dose escalation group:It adopts a \"\"3+3\"\" dose escalation design. Subjects were sequentially assigned to one of three dose groups, with a concentration of 2×105/mL in the low-dose group, 2×106/mL in the middle-dose group, and 2×107/mLparticles/mL in the high-dose group. The principle of dose escalation was strictly followed, starting with the low dose and increasing sequentially, and 3 subjects were included in each group.\n7 days after the first patient in each dose group was dosed, the 2nd to 3rd patients could be dosed; A seven-day safety assessment for all participants in the previous dose group was completed before the next dose group could be conducted. If the criteria for terminating the trial are met during the dose escalation process, the investigator will discuss and decide to terminate the trial or return to the previous dose group to continue the trial.;Case expansion group (control group):Tacrolimus in combination with 308 phototherapy;Case Expansion Group (Experimental Group):Hair follicle organoid therapy;"], "external_ids": {}}
|
| 451 |
{"id": 1714, "kind": "trial", "key": "ctri_2025_03_083595", "name": "CTRI/2025/03/083595", "aliases": ["CTRI/2025/03/083595", "Assessment and comparison of social acceptance, body image, self esteem and quality of life in patients with facial vitiligo versus facial melasma-A comparative cross sectional study"], "external_ids": {"ictrp": "CTRI/2025/03/083595"}}
|
| 452 |
-
{"id": 1715, "kind": "drug", "key": "control", "name": "Control", "aliases": ["Control"], "external_ids": {}}
|
| 453 |
{"id": 1716, "kind": "trial", "key": "ctri_2025_03_083332", "name": "CTRI/2025/03/083332", "aliases": ["CTRI/2025/03/083332", "Use of Shwitrari tail and Shwitra Nashan churna on Viruddha Aahar Jnyanya Shwitra(Vitiligo)."], "external_ids": {"ictrp": "CTRI/2025/03/083332"}}
|
| 454 |
{"id": 1717, "kind": "trial", "key": "ctri_2025_03_083363", "name": "CTRI/2025/03/083363", "aliases": ["CTRI/2025/03/083363", "A clinical study to evaluate the effect and safety of Topical Tacrolimus and Topical Tofacitinib ointments for treatment in patchy loss of skin pigmentation."], "external_ids": {"ictrp": "CTRI/2025/03/083363"}}
|
| 455 |
{"id": 1718, "kind": "drug", "key": "topical_tacrolimus_0_1_ointment_twice_a_day_for_12_weeks_control", "name": "Topical Tacrolimus 0.1% ointment: Twice a day for 12 weeks\nControl", "aliases": ["Topical Tacrolimus 0.1% ointment: Twice a day for 12 weeks\nControl"], "external_ids": {}}
|
|
@@ -1547,7 +1547,7 @@
|
|
| 1547 |
{"id": 2816, "kind": "drug", "key": "product_name_protopic_product_code_27315_pharmaceutical_form_ointment_inn_or_proposed_inn_tacrolimusum_monohydricum_conc", "name": "Product Name: Protopic\nProduct Code: 27315\nPharmaceutical Form: Ointment\nINN or Proposed INN: Tacrolimusum monohydricum\nConcentration unit: % percent\nConcentration type: equal\nConcentration number: 0.1-", "aliases": ["Product Name: Protopic\nProduct Code: 27315\nPharmaceutical Form: Ointment\nINN or Proposed INN: Tacrolimusum monohydricum\nConcentration unit: % percent\nConcentration type: equal\nConcentration number: 0.1-"], "external_ids": {}}
|
| 1548 |
{"id": 2817, "kind": "trial", "key": "euctr2004_003215_22_es", "name": "EUCTR2004-003215-22-ES", "aliases": ["EUCTR2004-003215-22-ES", "Ensayo clínico piloto, unicéntrico, aleatorizado, doble ciego, con dos grupos paralelos sobre el efecto del Tacalcitol en pacientes afectos de vitíligo."], "external_ids": {"ictrp": "EUCTR2004-003215-22-ES"}}
|
| 1549 |
{"id": 2818, "kind": "drug", "key": "product_name_bonalfa_0_0004_pomada_50_g_product_code_7069034_pharmaceutical_form_ointment_inn_or_proposed_inn_tacalcitol", "name": "Product Name: Bonalfa (0'0004% pomada 50 g)\nProduct Code: 7069034\nPharmaceutical Form: Ointment\nINN or Proposed INN: TACALCITOL\nConcentration unit: µg microgram(s)\nConcentration type: equal\nConcentration number: 4-\nPharmaceutical form of the placebo: Ointment\nRoute of administration of the placebo: Cutaneous use", "aliases": ["Product Name: Bonalfa (0'0004% pomada 50 g)\nProduct Code: 7069034\nPharmaceutical Form: Ointment\nINN or Proposed INN: TACALCITOL\nConcentration unit: µg microgram(s)\nConcentration type: equal\nConcentration number: 4-\nPharmaceutical form of the placebo: Ointment\nRoute of administration of the placebo: Cutaneous use"], "external_ids": {}}
|
| 1550 |
-
{"id": 8360, "kind": "drug", "key": "potassium_hydroxide", "name": "potassium hydroxide", "aliases": ["potassium hydroxide"], "external_ids": {"mesh": "C029943"}}
|
| 1551 |
{"id": 8361, "kind": "trial", "key": "ctri_2025_04_083985", "name": "CTRI/2025/04/083985", "aliases": ["CTRI/2025/04/083985", "Effect of nimbhadi churna in the treatment of shwitra"], "external_ids": {"ictrp": "CTRI/2025/04/083985"}}
|
| 1552 |
{"id": 8362, "kind": "trial", "key": "ctri_2023_06_053856", "name": "CTRI/2023/06/053856", "aliases": ["CTRI/2023/06/053856", "Treatment Of Leucoderma By Ammi Visnaga"], "external_ids": {"ictrp": "CTRI/2023/06/053856"}}
|
| 1553 |
{"id": 8363, "kind": "drug", "key": "ammi_visnaga_mother_tincture_5_drops_in_10_ml_of_water_daily_for_7_days_repeated_at_15_days_interval_control", "name": "Ammi visnaga Mother Tincture: 5 Drops In 10 Ml of Water Daily For 7 Days Repeated At 15 Days Interval\nControl", "aliases": ["Ammi visnaga Mother Tincture: 5 Drops In 10 Ml of Water Daily For 7 Days Repeated At 15 Days Interval\nControl"], "external_ids": {}}
|
|
|
|
| 449 |
{"id": 1712, "kind": "trial", "key": "chictr2500099959", "name": "ChiCTR2500099959", "aliases": ["ChiCTR2500099959", "Clinical study of hair follicle organoids for the treatment of vitiligo"], "external_ids": {"ictrp": "ChiCTR2500099959"}}
|
| 450 |
{"id": 1713, "kind": "drug", "key": "dose_escalation_group_it_adopts_a_3_3_dose_escalation_design_subjects_were_sequentially_assigned_to_one_of_three_dose_gr", "name": "Dose escalation group:It adopts a \"\"3+3\"\" dose escalation design. Subjects were sequentially assigned to one of three dose groups, with a concentration of 2×105/mL in the low-dose group, 2×106/mL in the middle-dose group, and 2×107/mLparticles/mL in the high-dose group. The principle of dose escalation was strictly followed, starting with the low dose and increasing sequentially, and 3 subjects were included in each group.\n7 days after the first patient in each dose group was dosed, the 2nd to 3rd patients could be dosed; A seven-day safety assessment for all participants in the previous dose group was completed before the next dose group could be conducted. If the criteria for terminating the trial are met during the dose escalation process, the investigator will discuss and decide to terminate the trial or return to the previous dose group to continue the trial.;Case expansion group (control group):Tacrolimus in combination with 308 phototherapy;Case Expansion Group (Experimental Group):Hair follicle organoid therapy;", "aliases": ["Dose escalation group:It adopts a \"\"3+3\"\" dose escalation design. Subjects were sequentially assigned to one of three dose groups, with a concentration of 2×105/mL in the low-dose group, 2×106/mL in the middle-dose group, and 2×107/mLparticles/mL in the high-dose group. The principle of dose escalation was strictly followed, starting with the low dose and increasing sequentially, and 3 subjects were included in each group.\n7 days after the first patient in each dose group was dosed, the 2nd to 3rd patients could be dosed; A seven-day safety assessment for all participants in the previous dose group was completed before the next dose group could be conducted. If the criteria for terminating the trial are met during the dose escalation process, the investigator will discuss and decide to terminate the trial or return to the previous dose group to continue the trial.;Case expansion group (control group):Tacrolimus in combination with 308 phototherapy;Case Expansion Group (Experimental Group):Hair follicle organoid therapy;"], "external_ids": {}}
|
| 451 |
{"id": 1714, "kind": "trial", "key": "ctri_2025_03_083595", "name": "CTRI/2025/03/083595", "aliases": ["CTRI/2025/03/083595", "Assessment and comparison of social acceptance, body image, self esteem and quality of life in patients with facial vitiligo versus facial melasma-A comparative cross sectional study"], "external_ids": {"ictrp": "CTRI/2025/03/083595"}}
|
| 452 |
+
{"id": 1715, "kind": "drug", "key": "control", "name": "Control", "aliases": ["Control"], "external_ids": {"chembl": "CHEMBL2108771"}}
|
| 453 |
{"id": 1716, "kind": "trial", "key": "ctri_2025_03_083332", "name": "CTRI/2025/03/083332", "aliases": ["CTRI/2025/03/083332", "Use of Shwitrari tail and Shwitra Nashan churna on Viruddha Aahar Jnyanya Shwitra(Vitiligo)."], "external_ids": {"ictrp": "CTRI/2025/03/083332"}}
|
| 454 |
{"id": 1717, "kind": "trial", "key": "ctri_2025_03_083363", "name": "CTRI/2025/03/083363", "aliases": ["CTRI/2025/03/083363", "A clinical study to evaluate the effect and safety of Topical Tacrolimus and Topical Tofacitinib ointments for treatment in patchy loss of skin pigmentation."], "external_ids": {"ictrp": "CTRI/2025/03/083363"}}
|
| 455 |
{"id": 1718, "kind": "drug", "key": "topical_tacrolimus_0_1_ointment_twice_a_day_for_12_weeks_control", "name": "Topical Tacrolimus 0.1% ointment: Twice a day for 12 weeks\nControl", "aliases": ["Topical Tacrolimus 0.1% ointment: Twice a day for 12 weeks\nControl"], "external_ids": {}}
|
|
|
|
| 1547 |
{"id": 2816, "kind": "drug", "key": "product_name_protopic_product_code_27315_pharmaceutical_form_ointment_inn_or_proposed_inn_tacrolimusum_monohydricum_conc", "name": "Product Name: Protopic\nProduct Code: 27315\nPharmaceutical Form: Ointment\nINN or Proposed INN: Tacrolimusum monohydricum\nConcentration unit: % percent\nConcentration type: equal\nConcentration number: 0.1-", "aliases": ["Product Name: Protopic\nProduct Code: 27315\nPharmaceutical Form: Ointment\nINN or Proposed INN: Tacrolimusum monohydricum\nConcentration unit: % percent\nConcentration type: equal\nConcentration number: 0.1-"], "external_ids": {}}
|
| 1548 |
{"id": 2817, "kind": "trial", "key": "euctr2004_003215_22_es", "name": "EUCTR2004-003215-22-ES", "aliases": ["EUCTR2004-003215-22-ES", "Ensayo clínico piloto, unicéntrico, aleatorizado, doble ciego, con dos grupos paralelos sobre el efecto del Tacalcitol en pacientes afectos de vitíligo."], "external_ids": {"ictrp": "EUCTR2004-003215-22-ES"}}
|
| 1549 |
{"id": 2818, "kind": "drug", "key": "product_name_bonalfa_0_0004_pomada_50_g_product_code_7069034_pharmaceutical_form_ointment_inn_or_proposed_inn_tacalcitol", "name": "Product Name: Bonalfa (0'0004% pomada 50 g)\nProduct Code: 7069034\nPharmaceutical Form: Ointment\nINN or Proposed INN: TACALCITOL\nConcentration unit: µg microgram(s)\nConcentration type: equal\nConcentration number: 4-\nPharmaceutical form of the placebo: Ointment\nRoute of administration of the placebo: Cutaneous use", "aliases": ["Product Name: Bonalfa (0'0004% pomada 50 g)\nProduct Code: 7069034\nPharmaceutical Form: Ointment\nINN or Proposed INN: TACALCITOL\nConcentration unit: µg microgram(s)\nConcentration type: equal\nConcentration number: 4-\nPharmaceutical form of the placebo: Ointment\nRoute of administration of the placebo: Cutaneous use"], "external_ids": {}}
|
| 1550 |
+
{"id": 8360, "kind": "drug", "key": "potassium_hydroxide", "name": "potassium hydroxide", "aliases": ["potassium hydroxide"], "external_ids": {"mesh": "C029943", "chembl": "CHEMBL1200706"}}
|
| 1551 |
{"id": 8361, "kind": "trial", "key": "ctri_2025_04_083985", "name": "CTRI/2025/04/083985", "aliases": ["CTRI/2025/04/083985", "Effect of nimbhadi churna in the treatment of shwitra"], "external_ids": {"ictrp": "CTRI/2025/04/083985"}}
|
| 1552 |
{"id": 8362, "kind": "trial", "key": "ctri_2023_06_053856", "name": "CTRI/2023/06/053856", "aliases": ["CTRI/2023/06/053856", "Treatment Of Leucoderma By Ammi Visnaga"], "external_ids": {"ictrp": "CTRI/2023/06/053856"}}
|
| 1553 |
{"id": 8363, "kind": "drug", "key": "ammi_visnaga_mother_tincture_5_drops_in_10_ml_of_water_daily_for_7_days_repeated_at_15_days_interval_control", "name": "Ammi visnaga Mother Tincture: 5 Drops In 10 Ml of Water Daily For 7 Days Repeated At 15 Days Interval\nControl", "aliases": ["Ammi visnaga Mother Tincture: 5 Drops In 10 Ml of Water Daily For 7 Days Repeated At 15 Days Interval\nControl"], "external_ids": {}}
|
relations.jsonl
CHANGED
|
@@ -1,3 +1,3 @@
|
|
| 1 |
version https://git-lfs.github.com/spec/v1
|
| 2 |
-
oid sha256:
|
| 3 |
-
size
|
|
|
|
| 1 |
version https://git-lfs.github.com/spec/v1
|
| 2 |
+
oid sha256:67b31375c50d98771d58fc4a583ea4b445483e2bdc6722fd78cc2a8a9dcaa3c1
|
| 3 |
+
size 19484721
|